CN103565745A - 用于治疗中风的神经保护性脂质体组合物和方法 - Google Patents

用于治疗中风的神经保护性脂质体组合物和方法 Download PDF

Info

Publication number
CN103565745A
CN103565745A CN201210356929.9A CN201210356929A CN103565745A CN 103565745 A CN103565745 A CN 103565745A CN 201210356929 A CN201210356929 A CN 201210356929A CN 103565745 A CN103565745 A CN 103565745A
Authority
CN
China
Prior art keywords
composition
elip
liposome
liposomes
apoplexy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201210356929.9A
Other languages
English (en)
Chinese (zh)
Inventor
黄韶玲
M·E·克莱格曼
耿永健
金亨建
D·D·麦克弗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Priority to CN201910643063.1A priority Critical patent/CN110464709A/zh
Priority to EP13828100.1A priority patent/EP2882422B1/en
Priority to AU2013299453A priority patent/AU2013299453B2/en
Priority to US14/420,429 priority patent/US10369103B2/en
Priority to EP21170435.8A priority patent/EP3932394B1/en
Priority to CA3132444A priority patent/CA3132444C/en
Priority to PCT/US2013/054349 priority patent/WO2014026117A2/en
Priority to JP2015526733A priority patent/JP6297040B2/ja
Priority to CA2881096A priority patent/CA2881096C/en
Publication of CN103565745A publication Critical patent/CN103565745A/zh
Priority to US16/453,252 priority patent/US10973764B2/en
Priority to US17/229,627 priority patent/US11872312B2/en
Priority to US18/540,656 priority patent/US20240398708A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201210356929.9A 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法 Pending CN103565745A (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201910643063.1A CN110464709A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法
CA3132444A CA3132444C (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
AU2013299453A AU2013299453B2 (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
US14/420,429 US10369103B2 (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
EP21170435.8A EP3932394B1 (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
EP13828100.1A EP2882422B1 (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
PCT/US2013/054349 WO2014026117A2 (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
JP2015526733A JP6297040B2 (ja) 2012-08-10 2013-08-09 脳卒中の治療のための神経保護リポソーム組成物および方法
CA2881096A CA2881096C (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
US16/453,252 US10973764B2 (en) 2012-08-10 2019-06-26 Neuroprotective liposome compositions and methods for treatment of stroke
US17/229,627 US11872312B2 (en) 2012-08-10 2021-04-13 Neuroprotective liposome compositions and methods for treatment of stroke
US18/540,656 US20240398708A1 (en) 2012-08-10 2023-12-14 Neuroprotective liposome compositions and methods for treatment of stroke

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682130P 2012-08-10 2012-08-10
US61/682,130 2012-08-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910643063.1A Division CN110464709A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法

Publications (1)

Publication Number Publication Date
CN103565745A true CN103565745A (zh) 2014-02-12

Family

ID=50039028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210356929.9A Pending CN103565745A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法
CN201910643063.1A Pending CN110464709A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910643063.1A Pending CN110464709A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法

Country Status (7)

Country Link
US (4) US10369103B2 (enExample)
EP (2) EP3932394B1 (enExample)
JP (1) JP6297040B2 (enExample)
CN (2) CN103565745A (enExample)
AU (1) AU2013299453B2 (enExample)
CA (2) CA3132444C (enExample)
WO (1) WO2014026117A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
WO2014145443A2 (en) 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
US10456483B2 (en) 2014-12-03 2019-10-29 University Of Cincinnati Gas-encapsulated acoustically responsive stabilized microbubbles and methods for treating cardiovascular disease
JP6622822B2 (ja) * 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
CZ307851B6 (cs) * 2017-02-14 2019-06-26 Ústav experimentální medicíny AV ČR, v. v. i. Léčebný přípravek k prevenci a léčení zánětlivých a degenerativních onemocnění
JP2020033304A (ja) * 2018-08-30 2020-03-05 医療法人ふじいやさか 薬剤又はサプリメント、組成物、及び水素供給器の使用
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法
JP2022144013A (ja) * 2021-03-18 2022-10-03 橋本電子工業株式会社 抗血栓リポソーム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031243A1 (en) * 1997-09-15 2001-10-18 Imarx Pharmaceutical Corp. Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions
CN1668315A (zh) * 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
US20080175893A1 (en) * 2006-10-16 2008-07-24 Northwestern University Gas-containing liposomes
US20120087956A1 (en) * 2007-12-22 2012-04-12 Simpkins Cuthbert O Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
WO1993020802A1 (en) 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5858399A (en) 1992-04-09 1999-01-12 Northwestern University Acoustically reflective liposomes and methods to make and use the same
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5545396A (en) 1994-04-08 1996-08-13 The Research Foundation Of State University Of New York Magnetic resonance imaging using hyperpolarized noble gases
US6123919A (en) 1994-04-08 2000-09-26 The Trustees Of Princeton University Magnetic resonance imaging using hyperpolarized noble gases
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997015311A1 (fr) 1995-10-20 1997-05-01 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Composition a base de monoxyde d'azote en tant que medicament
CA2263705C (en) 1996-08-19 2007-12-04 Nancy Smyth-Templeton Novel sandwich liposome complexes comprising a biologically active agent
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6050444A (en) 1998-07-22 2000-04-18 Sugg; James Wesley Consumable beverage dispenser with one-way valve
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
DE19933704A1 (de) 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
GB9917822D0 (en) 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
DE10054563A1 (de) 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
AU2002220881A1 (en) 2000-12-04 2002-06-18 Uws Ventures Limited Noble gas complexes
EP1228770B1 (en) 2001-01-31 2005-07-13 Bracco Research S.A. Lyophilisable contrast agent comprising gas microbubbles
EP1399189A1 (en) 2001-06-11 2004-03-24 Universite De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
AU2002324723B2 (en) 2001-08-16 2007-10-25 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies
US7202089B2 (en) 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
GB0209998D0 (en) 2002-05-01 2002-06-12 Protexeon Ltd Use
DE10328272A1 (de) 2002-06-22 2004-01-15 Messer Griesheim Gmbh Medikament mit Xenon und NO
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
WO2004004782A1 (de) 2002-07-05 2004-01-15 Messer Griesheim Gmbh Xenon enthaltendes adjuvans
GB0218153D0 (en) 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
DE10336778B4 (de) 2002-08-10 2010-09-16 Air Liquide Deutschland Gmbh Stabilisierung eines Patienten mit einem xenonhaltigen Gas
DE10336768B4 (de) 2002-08-10 2010-09-09 Air Liquide Deutschland Gmbh Medikament zur Verbesserung der Sauerstoffutilation
AU2003279004B2 (en) 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
CA2547531C (en) 2002-11-26 2013-11-12 Seacoast Neuroscience, Inc. Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
FR2849779B1 (fr) 2003-01-15 2006-07-14 Air Liquide Sante Sa Utilisation de xenon ou de n2o dans le traitement des deteriorations cellulaires cerebrales post-ischemiques
US7198179B2 (en) 2003-02-25 2007-04-03 Therox, Inc. System for storing and dispensing a gas-solubilized product
US20060019868A1 (en) 2004-01-30 2006-01-26 Pendharkar Sanyog M Hemostatic compositions and devices
ES2298815T3 (es) 2003-10-10 2008-05-16 Protexeon Limited Uso de xenon con hipotermia para tratar asfixia neonatal.
EP1552840A1 (en) 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
EP1714642A1 (en) * 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery
WO2006126244A1 (ja) 2005-05-23 2006-11-30 Mebiopharm Co., Ltd. ガス封入リポソームの製造法
CN103860390A (zh) 2006-05-09 2014-06-18 高露洁-棕榄公司 口腔护理方案
US20080187605A1 (en) 2007-02-02 2008-08-07 Olney John W Preventing pathological nerve cell suicide (neuroapoptosis) in immature nervous systems
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
EP1980260A1 (en) 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
CA2685446A1 (en) 2007-04-30 2008-11-06 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
US20110104052A1 (en) 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
US8765172B2 (en) 2007-12-10 2014-07-01 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
CL2007003772A1 (es) 2007-12-21 2008-04-25 Vulco Sa Procedimiento para la fabricacion de un mandril flexible de poliuretano, que contiene un alma metalica que comprende recubrir con goma un alma metalica, aplicar desmoldante, precalentar el conjunto, curar el poliuretano y enfriar el codo.
DK2349300T3 (da) 2008-11-10 2019-12-02 Moleac Pte Ltd Kombinationsterapi til behandling af patienter med neurologiske lidelser og cerebralt infarkt
CA2749698C (en) 2009-01-30 2017-08-01 Cuthbert O. Simpkins Resuscitation fluid
FR2944969B1 (fr) 2009-04-29 2011-08-26 Air Liquide Utilisation de n2o gazeux dans le traitement des douleurs chroniques
DK3100728T3 (da) * 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme
EP2445339B1 (en) * 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
US8974818B2 (en) 2010-01-20 2015-03-10 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
CA2806639C (en) 2010-08-09 2020-10-20 Bracco Suisse Sa Targeted gas-filled microvesicles
WO2012096697A1 (en) * 2011-01-14 2012-07-19 Simpkins Cuthbert O Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US20130247924A1 (en) 2012-03-23 2013-09-26 Mark Scatterday Electronic cigarette having a flexible and soft configuration
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031243A1 (en) * 1997-09-15 2001-10-18 Imarx Pharmaceutical Corp. Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions
CN1668315A (zh) * 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
US20080175893A1 (en) * 2006-10-16 2008-07-24 Northwestern University Gas-containing liposomes
US20120087956A1 (en) * 2007-12-22 2012-04-12 Simpkins Cuthbert O Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries

Also Published As

Publication number Publication date
AU2013299453A1 (en) 2015-02-26
US10973764B2 (en) 2021-04-13
US20240398708A1 (en) 2024-12-05
US11872312B2 (en) 2024-01-16
US20210378959A1 (en) 2021-12-09
JP2015528441A (ja) 2015-09-28
WO2014026117A3 (en) 2014-10-23
EP3932394A1 (en) 2022-01-05
EP2882422B1 (en) 2021-04-28
EP2882422A4 (en) 2016-03-16
AU2013299453B2 (en) 2017-12-14
WO2014026117A2 (en) 2014-02-13
US20150216800A1 (en) 2015-08-06
US20200101015A1 (en) 2020-04-02
US10369103B2 (en) 2019-08-06
CN110464709A (zh) 2019-11-19
JP6297040B2 (ja) 2018-03-20
CA2881096C (en) 2021-11-16
EP3932394B1 (en) 2024-08-07
CA3132444C (en) 2023-11-07
EP2882422A2 (en) 2015-06-17
CA2881096A1 (en) 2014-02-13
CA3132444A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
CN103565745A (zh) 用于治疗中风的神经保护性脂质体组合物和方法
US7976743B2 (en) Gas-containing liposomes
Shuaib et al. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase
JP5795537B2 (ja) 中枢神経系への対流増進送達のためのリポソーム組成物
EP2111224A2 (en) Targeting ncca-atp channel for organ protection following ischemic episode
EP3359134B1 (en) Compositions and compositions for use in on-demand high-efficiency triggerable anesthesia
US20240358984A1 (en) Ultrasound delivery
US20140275261A1 (en) Diclofenac parenteral compositions
Cadichon et al. Neuroprotective effect of the surfactant poloxamer 188 in a model of intracranial hemorrhage in rats
JP2009519250A (ja) リポソーム組成物
CN1321697C (zh) 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法
Uhl et al. Reduction of skin flap necrosis by transdermal application of buflomedil bound to liposomes
JP2008542308A (ja) ファルネシルジベンゾジアゼピノン製剤
KR20230005120A (ko) 혈관종의 치료를 위한 방법 및 조성물
HK1193995A (en) Neuroprotective liposome compositions and methods for treatment of stroke
US20250360095A1 (en) Pharmaceutical compositions for use in treating pain
HK40017554A (en) Neuroprotective liposome compositions and methods for treatment of stroke
RU2812902C2 (ru) Фармацевтические композиции для применения при лечении боли

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193995

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20140212

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1193995

Country of ref document: HK